Drug Database
DU

dutasteride + tamsulosin (Jalyn / Combodart / Duodart)

✓ Approved

GSK · ADRA1A · Small Molecule

What is dutasteride + tamsulosin?

dutasteride + tamsulosin is a small molecule developed by GSK. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesJalyn, Combodart, Duodart
CompanyGSK
Drug ClassSmall Molecule
Molecular TargetADRA1A, SRD5A1, SRD5A2
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, GSK

Mechanism of Action

Molecular Targets

dutasteride + tamsulosin acts on 3 molecular targets:

ADRA1Aadrenoceptor alpha 1A (ALPHA1AAR, ADRA1C)
SRD5A1steroid 5 alpha-reductase 1 (S5AR 1)
SRD5A2steroid 5 alpha-reductase 2 ()
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

dutasteride + tamsulosin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Reproductive system and breast disordersBenign prostatic hyperplasia✓ Approved

Related Research Articles

PubMedIndian journal of orthopaedics2026-10-14

Efficacy and Safety of Tamsulosin in the Prevention of Postoperative Urinary Retention in Hip Fractures (TamPOUR-Hip Trial): A Randomized, Double-Blind Placebo-Controlled Study.

Tripathy Sujit Kumar SK, Varghese Paulson P, Khan Shahnawaz S, Patel Ranjan Kumar RK et al.

Postoperative urinary retention (POUR) is a common problem after hip fracture surgery in the elderly patients, leading to increased morbidity, catheterization, and prolonged hospitalization. Tamsulosin, an α1-adrenergic antagonist, may reduce POUR by decreasing bladder outlet resistance. This study evaluated the efficacy and safety of perioperative tamsulosin in preventing POUR in hip fracture patients. In this prospective, randomized, double-blind, placebo-controlled trial, 120 patients undergoing hip fracture surgery under spinal anaesthesia were allocated to receive either tamsulosin (0.4 mg daily) or placebo from admission until the second postoperative day. Foley catheter was removed on postoperative day one, and POUR was defined as post-void residual urine > 200 mL at six hours of catheter removal. Primary outcome was incidence of POUR; secondary outcomes included indwelling re-catheterization rates, urinary tract infections (UTIs), and adverse events. POUR was observed in 16.7% of patients in the tamsulosin group compared with 33.3% in the placebo group. Tamsulosin significantly reduced the pre-void bladder volume (311.3 ± 174.5 mL vs. 402.9 ± 198.4 mL; p = 0.008) and post-void residual urine volume (median 20 mL vs. 53.5 mL; p < 0.001). Re-catheterization was less frequent with tamsulosin (8.3% vs. 21.7%), though not statistically significant. Multivariate logistic regression analysis identified female sex, longer surgical duration, and blood loss as independent risk factors for POUR, while tamsulosin use was not found to be preventive. Adverse events, including dizziness and postural hypotension, were mild and self-limiting. Perioperative tamsulosin was safe and improved bladder emptying, but did not significantly reduce the incidence of POUR in elderly patients undergoing hip fracture surgery. Larger multicentric studies are needed to further clarify its role in this population.

PMID 42871280
Read full article →
PubMedJournal of molecular graphics & modelling2026-10-04

Structure-based drug repurposing for CDK6: Molecular docking and molecular dynamics characterization of FDA-approved non-oncological compounds.

Husain Syarifuddin S, Mohamed Ruzianisra R, Abd Halim Khairul Bariyyah KB, Chia Suet Lin SL

Cyclin-dependent kinase 6 (CDK6) contributes to G1-to-S cell-cycle progression and represents an established therapeutic target in hormone receptor-positive breast cancer. However, adverse effects and acquired resistance associated with current CDK4/6 inhibitors support continued investigation of alternative chemical scaffolds. In this study, a total of 319 FDA-approved non-oncological drugs were screened by molecular docking against the ATP-binding site of a predicted human CDK6-Cyclin D1 complex. The three highest-ranked compounds, dutasteride, danazol, and azelastine, were subsequently subjected to 100-ns molecular dynamics simulations, principal component analysis, MM-PBSA calculations, per-residue energy decomposition, and in silico pharmacokinetic profiling, with abemaciclib included as a reference inhibitor. All three repurposed candidates remained accommodated within the CDK6 binding pocket during their individual trajectories, although they exhibited different degrees of positional and conformational rearrangement and distinct energetic profiles. MM-PBSA ΔGtotal values were -20.47 ± 6.87 kcal/mol for dutasteride, -24.57 ± 5.09 kcal/mol for danazol, and -39.48 ± 6.10 kcal/mol for azelastine, compared with -41.79 ± 5.43 kcal/mol for abemaciclib. Per-residue decomposition showed that the candidates engaged overlapping regions of the CDK6 binding pocket while exhibiting distinct residue-level energetic contributions. Pharmacokinetic predictions further indicated differences in lipophilicity, gastrointestinal absorption, blood-brain barrier permeability, and P-glycoprotein substrate status among the selected compounds. Collectively, these findings provide structural, conformational, energetic, and pharmacokinetic characterization of dutasteride, danazol, and azelastine as candidate CDK6-binding scaffolds. Direct biochemical binding, kinase-inhibition, and cellular target-engagement studies are required to determine whether these predicted interactions have biological relevance.

PMID 42829998
Read full article →
PubMedNaunyn-Schmiedeberg's archives of pharmacology2026-10-02

Structural and proliferative responses of the prostate to abrupt versus tapered discontinuation of dutasteride in short- and long-term treated rats.

Morsi Ahmed A AA, Mersal Ezat A EA, Almuraikhi Nihal N, Hussein Ghaiath G et al.

This study aimed to assess the structural response of the normal prostate during its recovery following dutasteride discontinuation, either abruptly or gradually, in short-term or long-term treated rats. Fifty-six adult male Wistar rats were randomly allocated into seven groups: a control group and two dutasteride-treated groups (for 4 or 8 weeks, 0.5 mg/kg/day, orally). Furthermore, each corresponding group of the 4- and 8-week groups was subjected to abrupt or tapered drug discontinuation. At the end, blood samples were withdrawn for testosterone (T) and dihydrotestosterone (DHT) analyses. Ventral prostates (VP) were resected and subjected to hematoxylin and eosin (H&E) and Masson trichrome (MTC) staining. Besides, polymerase chain reaction (PCR) analysis and immunohistochemical identification of proliferating cell nuclear antigen (PCNA), caspase-3, and androgen receptors (AR) were performed. After 4 and 8 weeks of treatment, VP showed acinar trophic changes with reduced epithelial thickness in H&E, increased Masson-stained collagen distribution area, suppression of proliferation marker PCNA, activation of apoptosis, and AR downregulation. Discontinuation of dutasteride, whether abruptly or gradually, after short-term treatment showed prostate re-expansion and proliferation in both designs of withdrawal. However, in long-term dutasteride-treated rats, tapered discontinuation maintained the attained atrophic changes provoked in the prostate versus abrupt discontinuation. Abrupt discontinuation was associated with enhanced AR expression coupled with prostate proliferation and caspase-3 downregulation, leading to marked prostate rebound. As a preclinical study, it was concluded that the duration of exposure and the discontinuation design, whether abrupt or tapered, were found to have an impact on the prostate's recovery following dutasteride cessation. Abrupt discontinuation was linked to structural prostate rebound, which may be explained by AR upregulation.

PMID 42825925
Read full article →
PubMedJournal of pediatric urology2026-09-30

Efficacy and safety of medical expulsive therapy (MET) after extracorporeal shockwaves lithotripsy (SWL) in pediatric patients.

Hassan Ahmed Bakr Eldesouky ABE, Sheir Khaled Zaki KZ, Elshal Ahmed Mohamed AM, Bazeed Mahmoud Anees MA et al.

To evaluate the impact of tamsulosin as a post-SWL adjunctive treatment for pediatric urolithiasis. A randomized controlled trial (RCT) was carried out for children with renal stones amenable for SWL. Eligible children were randomized into 2 groups. Group 1 received tamsulosin (0.01 mg/kg once daily) for 2 weeks after each SWL session while group 2 served as a control. Stone clearance was defined as no residual fragments by low-dose non-contrast computed tomography (NCCT) at one and three months after last session. A total of 106 patients were included (53 in each group). Pre-SWL patients and stone criteria were comparable between both groups. Stone clearance was achieved in 43 patients (81.1%) in group 1 and 36 patients (67.9%) in group 2 (P = 0.119). Time to stone clearance was comparable for both groups (P = 0.110). Post-SWL complications were encountered in one patient (1.9%) in group 1 and three patients (5.7%) in group 2 (P = 0.308). Tamsulosin minor adverse effects were observed in 18.9%, but no patients discontinue treatment. Tamsulosin treatment following SWL for renal stones in children showed trends for increasing SFR and decreasing complications in comparison with control group. However, statistically significant differences were not achieved.

PMID 42816303
Read full article →
PubMedJournal of the European Academy of Dermatology and Venereology : JEADV2026-09-29

The safety and efficacy of doses higher than 0.5 mg/day of dutasteride in male androgenic alopecia.

Fernández Esparcia Pedro José PJ, Saceda-Corralo David D, Jiménez-Cahue Juan J, Gil-Redondo Rocío R et al.

PMID 42808698
Read full article →
PubMedCureus2026-09-27

Prescription Trends in the Management of Lower Urinary Tract Symptoms in Men: An Online Survey of Indian Urologists.

Patwardhan Prakash P, Palkar Santosh S, Sharma Rahul R, Kamble Sanjay S et al.

Background Lower urinary tract symptoms (LUTS), highly prevalent among aging men, adversely affect the quality of life. Pharmacological management has evolved with multiple drug classes, but real-world prescribing patterns in India have not been adequately studied. Thus, we evaluated prescription trends among Indian urologists for the management of male LUTS, assessed symptom patterns, evaluated factors influencing choice of fixed-dose combination (FDC), with special focus on silodosin-mirabegron FDC, and identified adverse events (AEs) and adherence. Methods This cross-sectional, questionnaire-based survey was performed over three months (January 2, 2026, to April 5, 2026) and included 110 Indian urologists actively managing male patients with LUTS. A 27-item structured questionnaire captured demographic characteristics, clinical practice patterns, and prescribing preferences for LUTS pharmacotherapy, including monotherapies, combination therapies, and FDCs, along with AEs and adherence. Results Of 135 urologists invited, 110 (81.48%) completed the survey. LUTS mainly involved a combination of storage, voiding, and post-micturition symptoms (n = 59, 53.6%). As a class, α1-blockers were the most frequently prescribed monotherapy (n = 109, 99.1% frequent/very frequent use), with silodosin (n = 98, 89.1%) and tamsulosin (n = 84, 76.4%) being most preferred. Use of dutasteride (n = 108, 98.2%) exceeded finasteride (n = 13, 11.8%). In patients with benign prostatic hyperplasia (BPH) with overactive bladder, silodosin-mirabegron was the most favored FDC (n = 97, 88.2%). FDCs of α1-blockers with muscarinic receptor antagonists and β-3 adrenergic agonists were preferred due to their proven efficacies (n = 83, 75.5% and n = 87, 79.1%, respectively) and lower incidences of AEs (n = 69, 62.7% and n = 80, 72.7%). Common AEs included dry mouth (n = 73, 66.4%), anejaculation (n = 69, 62.7%), and headache (n = 67, 60.9%). Moderate adherence (25%-75%) was reported by 95 (86.4%) urologists. Conclusion Adherence to pharmacotherapy, as assessed by participating urologists, was moderate, with urologists preferring silodosin as first-line therapy and silodosin-mirabegron FDC for mixed LUTS.

PMID 42799232
Read full article →

+3364 more articles available with a free account

Sign up free to view all articles →

Ask about dutasteride + tamsulosin